BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 10509043)

  • 1. The incidence of secondary leukemias.
    Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
    Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
    Haase D; Hanf V; Schulz T
    Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
    Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Leukemias induced by anticancer chemotherapies].
    Harousseau JL
    Bull Cancer; 1999 Nov; 86(11):929-38. PubMed ID: 10586109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
    Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and susceptibility to therapy-related myeloid neoplasms.
    Leone G; Fianchi L; Pagano L; Voso MT
    Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
    Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
    Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA; Le Beau MM
    Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology and therapy of secondary leukaemias.
    Dann EJ; Rowe JM
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):119-37. PubMed ID: 11355927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
    Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C
    Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.
    Levine EG; Bloomfield CD
    Semin Oncol; 1992 Feb; 19(1):47-84. PubMed ID: 1736370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
    Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
    J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.